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18 Frequency of delta F508 mutation in Venezuelan patients with
cystic ﬁbrosis
K. Sa´nchez1, O. Arcia1, X. Matute2, L. Mendiola2, I. Chaustre2, M. Villalon3,
H. Takiff1. 1Instituto Venezolano de Investigaciones Cientiﬁcas, Caracas,
Venezuela; 2Hospital JM de los Rios, Caracas, Venezuela; 3Hospital Algodonal de
Caracas, Caracas, Venezuela
Cystic Fibrosis (CF) is an autosomal recessive disease that is caused by over one
thousand mutations at the cystic ﬁbrosis conductance regulator gene (CFTR). The
aim of this study was to determine the frequency of the most frequent mutation
in this disease, called F508del, in Venezuelan patients with CF using Polymerase
Chain Reaction (PCR) and automated sequencing. We studied a ﬁrst group of
122 patients who are included in the national program of CF, which have symptoms
compatible with CF; without considering their provenance. The second group of
28 patients consisted in selected Venezuelans who were third generation and who
had at least two electrolyte determination tests above 60mEq/L. Detection of the
mutation was performed by PCR ampliﬁcation of a 500 (pb) CF gene segment
which contains the 508 protein position and automated sequencing at ABI3130XL.
In the ﬁrst group the F508del allelic frequency was 27% vs. 73% WT allele,
distributed in 22 homozygous and 26 compound heterozygote F508del/X, in the
second group the F508del allelic frequency was 23% vs. 77% WT allele, distributed
in 3 homozygous and 7 compound heterozygote F508del/WT, which suggests
no signiﬁcant (p> 0.05) inﬂuence of the provenance of the patients. Our results
are in agreement with previous reports that shows a F508del frequency highly
heterogeneous in Latin-American countries. This variation can result from mixed
populations with a different genetic background and news mutations in CFTR. The
result also indicates a high percentage of mutations causing FQ different to 508,
which should be included by other exons in the diagnosis of this disease in the
studied population.
19 Cystic ﬁbrosis transmembrane regulator gene mutations (CFTR)
in a tertiary care centre in Saudi Arabia
H.H. Banjar1. 1King Faisal Specialist Hospital and Research Center, Pediatrics,
Riyadh, Saudi Arabia
Objective: To determine the Cystic ﬁbrosis trans-membrane regulator gene (CFTR)
mutations in Saudi Arabia (KSA).
Study design: Retrospective chart review of all diagnosed CF patients and
determine their CFTR mutations during the period 2000–2011.
Results: A total of 317 patients were conﬁrmed to have CF with typical clinical
picture and sweat chloride test >60mmol/L. A total of 272 patients had their CFTR
examined, but only 241 (89%) patients have identiﬁed CFTR mutations. A total of
30 mutations were identiﬁed. Thirteen new mutations that have never been described
before in the medical literature were identiﬁed. Two hundred and ten patients (91%)
were homozygous and 20 (9%) patients were compound heterozygous. Eleven
patients their DNA could not be identiﬁed with the present testing.
Of the most common mutations that have been identiﬁed in descending frequency
were: 1548delG in 49 alleles (20.5%), DF-508 in 36 (15%), I1234V in 27 (11.5%),
3120+1G→A in 27 (11.5%), 711+1G→A in 24 (10.5%), and H139L in 20
(8.5%), which identiﬁed 77% of our CFTR mutations. ﬁfteen private mutation were
identiﬁed in 15 different families.
Conclusion: CFTR mutations in Saudi Arabia differ from that described in the
western world. Speciﬁc attention to the Saudi CFTR mutational patterns should be
applied during screening for such disease in this part of the world.
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Background: The knowledge about cystic ﬁbrosis (CF) in Egypt is very limited, and
a few reports have drawn attention to the existence of CF or CFTR-related disorders
in Egyptian population (Naguib et al., 2007). Furthermore, Egypt is a Mediterranean
North African country in addition to its pharaonic origin, and gene ﬂow to its
population occurred from Ethiopian, Greco-Roman, Arab, Turkish, French, English
settlers (Temtamy et al., 2010). Thus, the aim of this investigation was to perform
molecular analysis to identify the CFTR gene mutation in patients from Alexandria
(northern Egypt) to establish a list of Egyptian CFTR mutations.
Methods: DNA samples of 37 Egyptian patients were screened for the CFTR gene
mutations. All 27 exons and its ﬂanking introns of CFTR were ampliﬁed by PCR
using the published primer pairs and were studied by direct sequencing to identify
disease-causing mutations.
Results: As a result of this screening, only four mutations were found: c.1418delG
mutation in Exon11, c.2620−15C>G mutation in Exon16, and c.3877G>A
(p.Val1293Ile) mutation in exon 24 and a novel mutation c.3718−24G>A in
intron 22. Moreover, six polymorphisms were identiﬁed: c.1408A>G (M470V),
c.3870A>G (P1290P), c.2562T>G, c.1584G>A, c.4389G>A, c.869+11C>T. All
of these mutations and polymorphisms are not previously detected in the Egyptian
population except for the c.1408A>G (M470V) polymorphism.
Conclusion: Our preliminary data show that detected mutations in the CFTR gene
are strongly associated with CFTR-RD and only one disease-causing mutation was
identiﬁed. These ﬁndings will be used for planning future screening of CFTR
mutation in the Egyptian population.
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Introduction: CFTR p.Leu206Trp mutation is associated with residual transmem-
brane transport of chloride and mild CF.
Objective: To analyze the clinical differences between paediatric and adults CF pa-
tients who are compound heterozygous for p.Leu206Trp.
Methods: We examined clinical retrospective data of 12 paediatric patients
(group A: 6 males ranging 4 months to 12 y) and 10 adults (group B: 6 males,
27−51 y) harbouring p.Leu206Trp. Clinical symptoms, sweat test (ST), pulmonary
function (PF), pancreatic sufﬁciency (PS), air trapping (AT)/bronchiectasis (BC) on
CT scan and colonization with Pseudomonas aeruginosa (PA) or Staphylococcus
aureus (SA) were analyzed.
Results: Patients in group A were diagnosed by newborn screening (NS) and adults
at mean age of: 30 y. 8 adults were diagnosed by respiratory symptoms and had BC
on CT compared with only AT in 5 paediatric patients. ST values were borderline at
NS period (except in one case) but became positive with increasing age. In adults,
ST values were positive. All the patients except one were PS in both groups.
FEV1 predicted values were normal in group A but in 60% of adults values were
abnormal. PA and SA were isolated occasionally in paediatric patients but all adults
were chronic colonized.
Conclusions: We found clear differences between paediatric and adults patients
heterozygous for p.Leu206Trp. In childhood is associated with mild disease but
patients diagnosed in adulthood have lung disease, chronic colonization with PA/SA
and diffuse BC. Identiﬁcation at NS of the p.Leu206Trp in patients with other
identiﬁed mutation and borderline ST values could allow early treatment to delay
lung disease in adulthood.
